

Management and Treatment of Gastric Problems in Pregnant Women

Halima Sadia Hakim¹, Kohinoor Pervin², Rajesh Thangarajan³, Mohammed Shahjahan Kabir³, Lubna Shirin⁴, Flora Tasmin Nahar⁵, Jasvinder K⁶, Sivasuthan Letchumanan⁷, Nazmul MHM^{6*}

¹Faculty of Dentistry, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia

²Faculty of Medicine, AIMST University, Bedong, 08100, Kedah, Malaysia

³International Medical School, Management and Science University, Shah Alam 40100, Selangor, Malaysia

⁴Faculty of Medicine, Universiti Teknologi MARA, Sungai Buloh Campus, Jalan Hospital, Sungai Buloh, 47000 Selangor, Malaysia

⁵Gynaecology and Obstetrics Blue Unit, BIRDEM Women's and Children's Hospital, Segunbagicha, Dhaka, Bangladesh

⁶Graduate School of Medicine, Perdana University, Damansara Heights, 50490 Kuala Lumpur, Malaysia

⁷Faculty of T & CM, University of Cyberjaya, 63000 Cyberjaya, Selangor, Malaysia

Abstract

Gastric problems are common during pregnancy, affecting a significant proportion of women and presenting unique challenges for management and treatment. This review explores the prevalence, types, risk factors, and management approaches for gastric symptoms experienced by pregnant women. Hormonal changes, increased intra-abdominal pressure, and dietary/lifestyle factors contribute to the occurrence and severity of gastric problems, including heartburn, nausea, constipation, and bloating. The review discusses non-pharmacological strategies such as dietary modifications and lifestyle changes, along with safe pharmacological interventions, highlighting the importance of personalized care to optimize maternal comfort and fetal safety. Challenges in diagnosis and management, including safety considerations and individual variability in response to interventions, are also addressed. Overall, this paper emphasizes the significance of addressing gastric problems in prenatal care to improve maternal health outcomes and enhance the pregnancy experience.

Introduction

Gastric problems are common among pregnant women and can significantly impact maternal well-being and pregnancy outcomes. This introduction provides an overview of gastric problems during pregnancy, highlights the significance of managing these symptoms, and outlines the scope of the review. Overview of Gastric Problems During Pregnancy Pregnancy often brings about physiological changes that affect the digestive system, leading to various gastric symptoms. Common gastric problems experienced during pregnancy include heartburn, acid reflux, nausea, vomiting, constipation, and bloating [1-9]. These symptoms can occur at different stages of pregnancy due to hormonal fluctuations, increased intra-abdominal pressure from the growing uterus, and alterations in gastrointestinal motility [10-17].

Correspondence

Nazmul MHM

poorpiku@yahoo.com

Heartburn and acid reflux, for example, are prevalent in the later stages of pregnancy due to relaxation of the lower esophageal sphincter and displacement of the stomach. Nausea and vomiting, often referred to as morning sickness, are common in the first trimester and can vary in severity among women. Figure 1. Shows the gastrointestinal changes in pregnant women.




Figure 1. gastrointestinal changes[18]

Significance of Managing Gastric Symptoms in Pregnant Women Effective management of gastric symptoms during pregnancy is crucial for several reasons. Firstly, gastric problems can significantly impact a woman's quality of life and daily activities, leading to discomfort, disrupted sleep, and stress [3]. Severe symptoms like hyperemesis gravidarum (excessive vomiting) can result in dehydration, electrolyte imbalances, and nutritional deficiencies, posing risks to maternal and fetal health. Secondly, untreated or poorly managed gastric issues can lead to complications such as esophageal injury, hemorrhoids, and exacerbation of pre-existing conditions like gastroesophageal reflux disease (GERD). Additionally, maternal discomfort and distress from gastric symptoms can impact emotional well-being and overall pregnancy experience [19-29].

Scope of the Review

This review aims to provide a comprehensive analysis of the prevalence, types, risk factors, and management strategies for gastric problems in pregnant women. The scope encompasses a thorough examination of the physiological mechanisms underlying gastric symptoms during pregnancy, including hormonal influences

and mechanical factors like increased intra-abdominal pressure [4]. It also explores non-pharmacological approaches such as dietary modifications and lifestyle changes, as well as safe pharmacological interventions tailored to optimize maternal comfort and fetal safety. Furthermore, the review will address challenges in diagnosing and managing gastric symptoms during pregnancy, considering individual variability in symptom presentation and treatment response [30-34].

Prevalence and Types of Gastric Problems

Gastric problems are a common occurrence during pregnancy, impacting a significant proportion of women. This section explores the incidence of gastric symptoms among pregnant women and delves into the various types of gastric issues experienced during pregnancy, including heartburn, acid reflux, nausea, vomiting, constipation, hemorrhoids, bloating, and gas. Table 1 shows the percentage of gastric problems in pregnant women.

Table 1. Prevalence and Types of Gastric Problems During Pregnancy

Gastric Problem	Prevalence Among Pregnant Women (%)	Reference
Heartburn and Acid Reflux	30-50	[12]
Nausea and Vomiting	70-80	[13]
Constipation	40-50	[14]
Hemorrhoids	Varies	[15]
Bloating and Gas	Varies	[9]

Incidence of Gastric Symptoms in Pregnant Women

Research indicates that gastric symptoms are highly prevalent among pregnant women, affecting the majority during different stages of pregnancy. Studies suggest that up to 80% of pregnant women experience some form of gastrointestinal discomfort [5]. The incidence of specific gastric symptoms varies across pregnancy trimesters. For instance, heartburn and acid reflux become more pronounced in the second and third trimesters, affecting approximately 30% to 50% of pregnant women. Nausea and vomiting, commonly referred to as morning sickness, are reported by around 70% to 80% of pregnant women, predominantly in the first trimester. Constipation and bloating also affect a significant proportion of pregnant women, impacting approximately 40% to 50% due to hormonal and mechanical factors associated with pregnancy.

Types of Gastric Issues Experienced During Pregnancy

Heartburn and Acid Reflux: Heartburn is characterized by a burning sensation in the chest and throat and occurs when stomach acid flows back into the esophagus. During pregnancy, hormonal changes, particularly increased levels of progesterone, relax the lower esophageal sphincter, contributing to reflux symptoms [6]. The growing uterus further displaces the stomach, exacerbating reflux [35-38].

Nausea and Vomiting: Nausea and vomiting are common during pregnancy, especially in the first trimester. Hormonal fluctuations, altered gastric motility, and sensitivity to certain odors and foods contribute to these symptoms. Severe cases of nausea and vomiting, such as hyperemesis gravidarum, require medical

intervention to prevent dehydration and nutrient deficiencies [39-42].

Constipation and Hemorrhoids: Constipation is prevalent in pregnancy due to elevated levels of progesterone, which slow down intestinal motility and promote water absorption from the colon. This results in infrequent and hard stools, discomfort, and bloating.

Prolonged constipation can lead to hemorrhoids, swollen veins in the rectal area, further exacerbating discomfort and pain.

Bloating and Gas: Increased intra-abdominal pressure from the growing uterus and hormonal influences on gastrointestinal motility contribute to bloating and gas during pregnancy. Reduced intestinal motility leads to the accumulation of gas and discomfort, particularly in later stages of pregnancy.

Risk Factors for Gastric Issues During Pregnancy

Gastric problems during pregnancy are influenced by a variety of factors, ranging from hormonal changes to mechanical and lifestyle factors. Understanding these risk factors is crucial for effective management and prevention of gastric symptoms in pregnant women.

Hormonal Changes and Their Impact

Hormonal fluctuations, particularly increased levels of progesterone and estrogen, play a significant role in the development of gastric problems during pregnancy. Progesterone, known for its relaxing effect on smooth muscle tone, including the lower esophageal sphincter and intestinal muscles, can lead to reflux, constipation, and bloating [8]. The relaxation of the lower esophageal sphincter allows stomach acid to flow back into the esophagus, causing heartburn and acid reflux. Elevated estrogen levels influence gallbladder function, potentially leading to indigestion and exacerbating symptoms of heartburn.

Mechanical Factors: Uterine Pressure

As pregnancy progresses, the uterus expands to accommodate the growing fetus, exerting mechanical pressure on the surrounding organs, including the stomach and intestines. This increased intra-abdominal pressure can displace organs, impair normal digestive function, and contribute to gastric symptoms [9]. The displaced stomach may be compressed and displaced upward, leading to reduced gastric capacity and increased susceptibility to reflux and heartburn. Furthermore, the pressure exerted by the enlarged uterus on the intestines can impede normal peristalsis, contributing to constipation and bloating.

Dietary and Lifestyle Factors Contributing to Gastric Problems

Dietary and lifestyle choices can significantly impact the occurrence and severity of gastric problems during pregnancy [10]. Poor dietary habits, such as consuming spicy, fatty, or acidic foods, can trigger or worsen symptoms of heartburn and acid reflux. Excessive caffeine intake, smoking, and alcohol consumption are also known to exacerbate gastric issues. Inadequate hydration and lack of physical activity can contribute to constipation and bloating. Additionally, certain medications and supplements may interfere with digestive function and exacerbate gastric symptoms [43-50].

Management Approaches for Gastric Symptoms

Gastric symptoms during pregnancy can be effectively managed through a combination of non-pharmacological strategies and, when necessary, carefully selected pharmacological interventions. These approaches aim to alleviate discomfort while ensuring the safety and well-being of both the mother and the developing fetus.

Non-pharmacological Strategies

1. Dietary Modifications

Dietary adjustments play a crucial role in managing gastric symptoms during pregnancy. Pregnant women are advised to:

- Avoid spicy, fatty, and acidic foods that can trigger heartburn and exacerbate reflux.
- Opt for smaller, more frequent meals throughout the day to reduce gastric pressure and aid digestion.
- Include fiber-rich foods such as fruits, vegetables, and whole grains to promote regular bowel movements and prevent constipation.
- Stay hydrated by consuming adequate fluids, such as water and herbal teas, to maintain digestive health and prevent dehydration.

2. Lifestyle Changes

Certain lifestyle modifications can also contribute to the management of gastric symptoms:

- Maintain good posture, especially while eating and after meals, to minimize intra-abdominal pressure and reduce reflux.
- Engage in regular physical activity, such as walking or prenatal yoga, to promote gastrointestinal motility and overall well-being.
- Elevate the head of the bed or use additional pillows to keep the upper body elevated while sleeping, which can help reduce nighttime reflux symptoms.
- Avoid smoking and limit alcohol intake, as these habits can exacerbate gastric issues and pose risks to fetal development.

Pharmacological Interventions

When non-pharmacological strategies are insufficient in controlling gastric symptoms, healthcare providers may consider the use of pharmacological interventions. However, caution must be exercised due to potential risks associated with medication use during pregnancy.

1. Safety Considerations and Recommendations for Drug Use

Healthcare providers carefully assess the risks and benefits of pharmacological treatments, taking into account the gestational age, maternal health status, and potential impact on fetal development. Some commonly used medications for managing gastric symptoms during pregnancy include:

- **Antacids:** Over-the-counter antacids containing calcium carbonate or magnesium hydroxide can provide short-term relief from heartburn and acid reflux by neutralizing stomach acid.
- **H₂-receptor antagonists (H₂RAs):** Medications like ranitidine and famotidine reduce stomach acid production and are considered relatively safe options for managing moderate to severe reflux symptoms.
- **Proton pump inhibitors (PPIs):** PPIs such as omeprazole and pantoprazole are reserved for severe cases of reflux that do not respond to other treatments. They are recommended for short-term use and at the lowest effective dose due to potential risks to fetal development.

Healthcare providers inform pregnant women about the potential risks associated with medication use during pregnancy and prescribe medications judiciously, ensuring adherence to recommended dosages and treatment durations. Regular

monitoring and follow-up appointments are essential to evaluate treatment efficacy and ensure maternal and fetal well-being [51-55].

Challenges in Diagnosing and Managing Gastric Issues

Gastric issues during pregnancy present unique challenges in both diagnosis and management due to physiological changes and safety considerations associated with maternal and fetal health.

1. Diagnostic Challenges During Pregnancy

Diagnosing gastric problems in pregnant women can be challenging due to several factors:

- **Overlapping Symptoms:** Many common gastric symptoms during pregnancy, such as nausea, vomiting, and heartburn, can also be normal physiological changes associated with pregnancy itself [11]. Distinguishing between typical pregnancy-related symptoms and those indicative of underlying gastric issues requires careful evaluation.
- **Limited Diagnostic Tests:** The use of certain diagnostic tests, such as imaging studies (e.g., X-rays, CT scans), may be restricted during pregnancy due to potential risks to the developing fetus. Healthcare providers must rely on non-invasive diagnostic methods and clinical assessment to evaluate gastric symptoms accurately.
- **Patient Communication:** Pregnant women may downplay or overlook gastric symptoms, attributing them to pregnancy-related discomfort. Effective patient communication and detailed history-taking are essential to identify and address underlying gastric issues [56-61].

2. Safety Considerations in Treatment

The safety of treatment options for gastric problems is a critical consideration during pregnancy:

- **Medication Risks:** Many conventional medications used to manage gastric symptoms, such as proton pump inhibitors (PPIs) and certain antacids, have potential risks to fetal development. Healthcare providers must weigh the benefits of treatment against potential harms and opt for safer alternatives whenever possible.
- **Non-Pharmacological Approaches:** While non-pharmacological interventions are generally preferred during pregnancy, their efficacy and suitability for individual patients may vary. Healthcare providers must assess the appropriateness and safety of non-pharmacological strategies based on each woman's unique health status and pregnancy-related considerations.

3. Individual Variability in Response to Interventions

Pregnant women exhibit varying responses to interventions for gastric symptoms:

- **Hormonal Influence:** Differences in hormonal levels and responses to hormonal changes during pregnancy can impact the effectiveness of treatments targeting gastric symptoms. For example, the degree of smooth muscle relaxation caused by progesterone can vary among individuals, influencing the response to medications that target smooth muscle tone [62-64].
- **Underlying Conditions:** Pre-existing medical conditions, such as gastroesophageal reflux disease (GERD) or irritable bowel syndrome (IBS), can complicate the management of gastric symptoms during pregnancy. Women with underlying conditions may require more tailored treatment approaches and closer monitoring.

- Patient Preferences: Expectant mothers' preferences, beliefs, and concerns regarding treatment options can influence adherence and outcomes. Open communication and shared decision-making between healthcare providers and patients are essential to develop personalized care plans that align with individual preferences and needs.

Conclusion

Gastric problems during pregnancy are prevalent and can have significant implications for both maternal well-being and fetal development. The research on this topic highlights various gastric symptoms experienced by pregnant women, including heartburn, acid reflux, nausea, constipation, and bloating, with the severity often varying across different trimesters. These symptoms are influenced by hormonal changes, increased intra-abdominal pressure due to the growing uterus, and dietary/lifestyle factors. Managing these symptoms effectively is challenging due to overlapping symptoms, safety concerns regarding treatment options, and differences in individual responses to interventions.

Addressing gastric problems in prenatal care is crucial to ensure optimal outcomes for both mothers and babies. Untreated gastric symptoms can lead to complications such as dehydration, nutritional deficiencies, and reduced quality of life for pregnant women. Managing these symptoms effectively not only improves maternal comfort but also supports fetal growth and development. Early intervention is particularly important to mitigate potential risks to fetal health posed by persistent gastric issues during pregnancy.

Healthcare providers play a key role in addressing gastric problems in pregnant women. Routine screening for gastric symptoms during prenatal visits is essential for timely intervention and personalized care. Educating pregnant women about the physiological changes and risk factors associated with gastric problems empowers them to make informed decisions about their health. Healthcare providers should offer evidence-based interventions tailored to individual needs, which may include dietary modifications, lifestyle adjustments, and, when necessary, safe pharmacological interventions.

Expectant mothers can also contribute to managing gastric symptoms by maintaining a balanced diet, practicing good posture, and engaging in regular physical activity to promote gastrointestinal health. Open communication with healthcare providers is essential for discussing any persistent symptoms and exploring appropriate treatment options. By working collaboratively with healthcare teams and following personalized care plans, pregnant women can effectively manage gastric symptoms, improve their overall well-being, and optimize pregnancy outcomes. Ongoing research in this field is crucial to advance our understanding of gastric issues in pregnancy and develop more tailored and effective management strategies for pregnant women worldwide.

References

1. Longo, Sherri A., et al. "Gastrointestinal conditions during pregnancy." *Clinics in colon and rectal surgery* 23.02 (2010): 080-089.

2. Kumarasamy V, Anbazhagan D, Subramaniyan V, Vellasamy S. *Blastocystis sp., Parasite Associated with Gastrointestinal Disorders: An Overview of its Pathogenesis, Immune Modulation and Therapeutic Strategies.* *Curr Pharm Des.* 2018;24(27):3172-3175.
3. Subramaniyan V, Chakravarthi S, Jegasothy R, Seng WY, Fuloria NK, Fuloria S, Hazarika I, Das A. *Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy.* *Toxicol Rep.* 2021; 8:376-385.
4. Thapa R, Afzal O, Gupta G, Bhat AA, Almalki WH, Alzarea SI, Kazmi I, Altamimi ASA, Subramaniyan V, Thangavelu L, Singh SK, Dua K. *Unveiling the connection: Long-chain non-coding RNAs and critical signaling pathways in breast cancer.* *Pathol Res Pract.* 2023; 249:154736.
5. Fuloria S, Subramaniyan V, Karupiah S, Kumari U, Sathasivam K, Meenakshi DU, Wu YS, Guad RM, Udupa K, Fuloria NK. *A Comprehensive Review on Source, Types, Effects, Nanotechnology, Detection, and Therapeutic Management of Reactive Carbonyl Species Associated with Various Chronic Diseases.* *Antioxidants (Basel).* 2020;9(11):1075.
6. Bhat AA, Thapa R, Goyal A, Subramaniyan V, Kumar D, Gupta S, Singh SK, Dua K, Gupta G. *Curcumin-based nanoformulations as an emerging therapeutic strategy for inflammatory lung diseases.* *Future Med Chem.* 2023;15(7):583-586.
7. Malviya R, Raj S, Fuloria S, Subramaniyan V, Sathasivam K, Kumari U, Unnikrishnan Meenakshi D, Porwal O, Hari Kumar D, Singh A, Chakravarthi S, Kumar Fuloria N. *Evaluation of Antitumor Efficacy of Chitosan-Tamarind Gum Polysaccharide Polyelectrolyte Complex Stabilized Nanoparticles of Simvastatin.* *Int J Nanomedicine.* 2021;16:2533-2553.
8. Chinnasamy V, Subramaniyan V, Chandiran S, Kayarohanam S, Kannian DC, Velaga VSSR, Muhammad S. *Antiarthritic Activity of Achyranthes Aspera on Formaldehyde - Induced Arthritis in Rats.* *Open Access Maced J Med Sci.* 2019;7(17):2709-2714.
9. Bhat AA, Afzal O, Afzal M, Gupta G, Thapa R, Ali H, Hassan Almalki W, Kazmi I, Alzarea SI, Saleem S, Samuel VP, Gubbiyappa SK, Subramaniyan V. *MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting.* *Pathol Res Pract.* 2024;253:154991.
10. Subramaniyan V, Shaik S, Bag A, Manavalan G, Chandiran S. *Potential action of Rumex vesicarius (L.) against potassium dichromate and gentamicin induced nephrotoxicity in experimental rats.* *Pak J Pharm Sci.* 2018;31(2):509-516.

11. Sharma VK, Sharma PP, Mazumder B, Bhatnagar A, Subramaniyan V, Fuloria S, Fuloria NK. Mucoadhesive microspheres of glutaraldehyde crosslinked mucilage of Isabgol husk for sustained release of gliclazide. *J Biomater Sci Polym Ed.* 2021;32(11):1420-1449.
12. Mukerjee N, Maitra S, Ghosh A, Subramaniyan V, Sharma R. Exosome-mediated PROTACs delivery to target viral infections. *Drug Dev Res.* 2023;84(6):1031-1036.
13. Saminathan Kayarohanam, Vetriselvan Subramaniyan, Ashok Kumar Janakiraman, Madhan Kumar S. J. Antioxidant, Antidiabetic, and Antihyperlipidemic Activities of *Dolichandrone atrovirens* in Albino Wistar rats. *Research J. Pharm. and Tech.* 2019; 12(7): 3511-3516.
14. Venkateshan S, Subramaniyan V, Chinnasamy V, Chandiran S. Anti-oxidant and anti-hyperlipidemic activity of *Hemidesmus indicus* in rats fed with high-fat diet. *Avicenna Journal of Phytomedicine.* 2016;6(5):516-25.
15. Subasini U, Thenmozhi S, Sathyamurthy D, Vetriselvan S, Victor Rajamanickam G, Dubey GP. Pharmacognostic and phytochemical investigations of *Dioscorea bulbifera* L. *International Journal of Pharmacy & Life Sciences.* 2013;4(5).
16. Vetriselvan S, Subasini U, Velmurugan C, Muthuramu T, Revathy J. Anti-inflammatory activity of *Cucumis sativus* seed in carrageenan and xylene induced edema model using albino wistar rats. *Int. J. Biopharm.* 2013;4(1):34-7.
17. Huq MZ, Abdullah JY, Wong LS, Jamayet NB, Alam MK, Rashid QF, Husein A, Ahmad WM, Eusufzai SZ, Prasad S, Subramaniyan V. Clinical Applications of Artificial Intelligence and Machine Learning in Children with Cleft Lip and Palate-A Systematic Review. *International Journal of Environmental Research and Public Health.* 2022;19(17):10860.
18. Naxlex, Gastrointestinal Changes in pregnancy, <https://naxlex.com/nursing/study-guides/maternal-newborn-physiological-and-physical-changes-in-pregnancy-gastrointestinal-changes-in-pregnancy>
19. Puri A, Mohite P, Maitra S, Subramaniyan V, Kumarasamy V, Uti DE, Sayed AA, El-Demerdash FM, Algahtani M, El-kott AF, Shati AA. From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability. *Biomedicine & Pharmacotherapy.* 2024;170:116083.
20. De Rubis G, Paudel KR, Raju Allam VS, Malyala V, Subramaniyan V, Singh SK, Panth N, Gupta G, Hansbro PM, Chellappan DK, Dua K. Involvement of osteopontin, EpCAM, estrogen receptor-alpha, and carbonic anhydrase IX protein in managing lung cancer via Berberine-loaded liquid crystalline nanoparticles. *Pathology-Research and Practice.* 2023.
21. Prem P, Naveenkumar S, Kamaraj C, Ragavendran C, Priyadharsan A, Manimaran K, Alharbi NS, Rarokar N, Cherian T, Sugumar V, Thiruvengadam M. *Valeriana jatamansi* root extract a potent source for biosynthesis of silver nanoparticles and their biomedical applications, and photocatalytic decomposition. *Green Chemistry Letters and Reviews.* 2024;17(1):2305142.
22. Naveenkumar S, Kamaraj C, Prem P, Raja RK, Priyadharsan A, Alrefaei AF, Govindarajan RK, Thamarai R, Subramaniyan V. Eco-friendly synthesis of palladium nanoparticles using *Zaleya decandra*: Assessing mosquito larvicidal activity, zebrafish embryo developmental toxicity, and impacts on freshwater sludge worm *Tubifex tubifex*. *Journal of Environmental Chemical Engineering.* 2024;12(2):111912.
23. Azad AK, Sulaiman WM, Almoustafa H, Dayoob M, Kumarasamy V, Subramaniyan V, Alshehri JM, Khan AA. A dataset of microstructure features of electro-hydrodynamic assisted 5-fluorouracil-grafted alginate microbeads and physicochemical properties for effective colon targeted carriers drug delivery. *Data in Brief.* 2024:110202.
24. Sharma A, Sharma C, Sharma L, Wal P, Mishra P, Sachdeva N, Yadav S, Vargas De-La Cruz C, Arora S, Subramaniyan V, Rawat R, Behl T, Nandave M. Targeting the vivid facets of apolipoproteins as a cardiovascular risk factor in rheumatoid arthritis. *Can J Physiol Pharmacol.* 2024. doi: 10.1139/cjpp-2023-0259. Epub ahead of print. PMID: 38334084.
25. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, Wong LS. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. *Frontiers in Pharmacology.* 2024;15:1331062.
26. Mohite P, Yadav V, Pandhare R, Maitra S, Saleh FM, Saleem RM, Al-malky HS, Kumarasamy V, Subramaniyan V, Abdel-Daim MM, Uti DE. Revolutionizing Cancer Treatment: Unleashing the Power of Viral Vaccines, Monoclonal Antibodies, and Proteolysis-Targeting Chimeras in the New Era of Immunotherapy. *ACS Omega.* 2024.
27. Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya, Riya Thapa, Archana Gahtori, Moyad Shahwan, Vikas Jakhmola, Abhishek Tiwari, Mahish Kumar, Harish Dureja, Sachin Kumar Singh, Kamal Dua, Vinoth Kumarasamy, Vetriselvan Subramaniyan. *CircRNAs:*

- Pivotal modulators of TGF- β signalling in cancer pathogenesis. *Non-coding RNA Research*, 2024.
28. Azad AK, Lai J, Sulaiman WM, Almoustafa H, Alshehade SA, Kumarasamy V, Subramaniyan V. The Fabrication of Polymer-Based Curcumin-Loaded Formulation as a Drug Delivery System: An Updated Review from 2017 to the Present. *cancer cells*. 2017;69:1290-9.
 29. Nag S, Mitra O, Tripathi G, Adur I, Mohanto S, Nama M, Samanta S, Gowda BH, Subramaniyan V, Sundararajan V, Kumarasamy V. Nanomaterials-assisted Photothermal Therapy for Breast Cancer: State-of-the Advances and Future Perspectives. *Photodiagnosis and Photodynamic Therapy*. 2024;103959.
 30. Dhar J, Hazra A, Patra R, Kumar V, Subramaniyan V, Kumarasamy V, Mitra A, Sayed A, Aleya L, El-Demerdash F, Almutairi M. Unveiling *Curvularia tuberculata*-induced leaf anomalies in *Rhododendron ferrugineum*: implications in cultural-ecological conservation and harnessing microbial intervention in socio-economic advancement. *Frontiers in Microbiology*. 2023;14.
 31. Al Quwatli L, Lee MF, Wu YS, Poh CL, Batumalaie K, Ahemad N, Fuloria NK, Fuloria S, Sekar M, Subramaniyan V, Sarke MR. Antiviral Activity of Withanolide A Against Different Infectivity Phases of Dengue Virus Serotype 2 in Vero Cell Line. *Revista Brasileira de Farmacognosia*. 2024;1-9.
 32. Alharbi HM, Alqahtani T, Alamri AH, Kumarasamy V, Subramaniyan V, Babu KS. Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: a novel front in ovarian cancer precision therapeutics. *Frontiers in Pharmacology*. 2024;14:1276209.
 33. Mohamad Sobri WB, Naing NN, Wan-Arfah N, Abdullah S, Subramaniyan V, Wong LS, Selvaraj S. Prevalence and factors associated with excessive daytime sleepiness among Malaysian medical students. *Electron J Gen Med*. 2024; 21 (2): em571.
 34. Thapa R, Goyal A, Gupta G, Bhat AA, Singh SK, Subramaniyan V, Sharma S, Prasher P, Jakhmola V, Singh SK, Dua K. Recent developments in the role of protocatechuic acid in neurodegenerative disorders. *EXCLI journal*. 2023;22:595.
 35. Gupta G, Hussain MS, Thapa R, Dahiya R, Mahapatra DK, Bhat AA, Singla N, Subramaniyan V, Rawat S, Jakhmola V, Dua K. Hope on the horizon: Wharton's jelly mesenchymal stem cells in the fight against COVID-19. *Regenerative medicine*. 2023;18(9):675-8.
 36. Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR, Gupta G, Rajakumari V, Chinni SV, Ramachawolran G, Saleh FM. Development of new drug candidate for the inhibition of Lassa virus glycoprotein and nucleoprotein by modification of Evodiamine as Promising Therapeutic Agents. *Frontiers in Microbiology*.;14:1206872.
 37. Rarokar NR, Saoji SD, Deole NV, Gaikwad M, Pandey A, Kamaraj C, Chinni SV, Subramaniyan V, Ramachawolran G, Dharashivkar S. Preparation and formula optimization of cephalixin loaded transferosomal gel by QbD to enhance the transdermal delivery: In vitro, ex vivo and in vivo study. *Journal of Drug Delivery Science and Technology*. 2023;89:104968.
 38. Rizwi FA, Abubakar M, Puppala ER, Goyal A, Bhadrawamy CV, Naidu VG, Roshan S, Tazneem B, Almalki WH, Subramaniyan V, Rawat S. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer. *Journal of Environmental Pathology, Toxicology and Oncology*. 2023;42(4).
 39. Mujafarkani N, Ahamed FM, Babu KS, Debnath S, Sayed AA, Albadrani GM, Al-Ghadi MQ, Kumarasamy V, Subramaniyan V, Kamaraj C, Abdel-Daim MM. Unveiling a novel terpolymer-metal complex: A detailed exploration of synthesis, characterization, and its potential as an antimicrobial and antioxidant agent. *Heliyon*. 2023;9(10):e20459.
 40. Gholap AD, Gupta J, Kamandar P, Bhowmik DD, Rojekar S, Faiyazuddin M, Hatvate NT, Mohanto S, Ahmed MG, Subramaniyan V, Kumarasamy V. Harnessing nanovaccines for effective immunization— a special concern on COVID-19: facts, fidelity, and future prospective. *ACS biomaterials science & engineering*. 2023;10(1):271-97.
 41. Subramaniyan V, Lubau NS, Mukerjee N, Kumarasamy V. Alcohol-induced liver injury in signalling pathways and curcumin's therapeutic potential. *Toxicology Reports*. 2023;11:355-67.
 42. Mukherjee S, Nag S, Mukerjee N, Maitra S, Muthusamy R, Fuloria NK, Fuloria S, Adhikari MD, Anand K, Thorat N, Subramaniyan V. Unlocking exosome-based theragnostic signatures: deciphering secrets of ovarian cancer metastasis. *ACS omega*. 2023;8(40):36614-27.
 43. Kumarasamy V, Rajamanikam A, Anbazhagan D, Atroosh WM, Azzani M, Subramaniyan V, Abdullah SR. Systematic Review and Meta-Analysis: Epidemiology of Human Blastocystis spp. *Infection in Malaysia. Tropical Medicine and Infectious Disease*. 2023;8(8):415.
 44. Pandey A, Malviya R, Sundram S, Subramaniyan V.

- Issues and Challenges in Bioinformatics Tools for Clinical Trials. *Pharmaceutical industry 4.0: Future, Challenges & Application*. 2023:329.
45. Janakiraman AK, Afroze S, Chew YL, Yee YJ, Zenli C, Subramaniyan V, Kayarohanam S. An Expedition Towards Formulating Natural Face Serum with *Garcinia mangostana* (Mangosteen). *Current Trends in Biotechnology and Pharmacy*. 2023;17(4A (Supplement)):61-9.
46. Mukhopadhyay M, Mukherjee A, Subramaniyan V, Kumarasamy V, Sayed AA, El-Demerdash FM, Almutairi MH, Şuğan A, Dhara B, Mitra AK. Marvels of Bacilli in soil amendment for plant-growth promotion toward sustainable development having futuristic socio-economic implications. *Frontiers in microbiology*. 2023;14:1293302.
47. Ansori AN, Pratama MR, Mukerjee N, Subramaniyan V, Ramachawolran G, Akash S, Baeza J, Mahmood S, Mukerjee N, Subramaniyan V, Islam MR. Arli Aditya Parikesit, Indonesia International Institute for Life-Sciences (iL), Indonesia. *Computational Drug Discovery for Emerging Viral Infections*. 2023:137.
48. Kamaraj C, Naveenkumar S, Prem P, Ragavendran C, Subramaniyan V, Al-Ghanim KA, Malafaia G, Nicoletti M, Govindarajan M. Green synthesis and biophysical characterization of silver and palladium nanoparticles using *Laureliopsis philippiana*: A potent eco-friendly larvicide with negligible impact on zebrafish (*Danio rerio*). *Journal of Asia-Pacific Entomology*. 2023;26(4):102164.
49. Santhoshkumar T, Govindarajan RK, Kamaraj C, Alharbi NS, Manimaran K, Yanto DH, Subramaniyan V, Baek KH. Biological synthesis of nickel nanoparticles using extracellular metabolites of *Bacillus Sphaericus*: Characterization and vector-borne disease control applications. *South African Journal of Botany*. 2023;162:481-94.
50. Wan-Arfah N, Muzaimi M, Naing NN, Subramaniyan V, Wong LS, Selvaraj S. Prognostic factors of first-ever stroke patients in suburban Malaysia by comparing regression models. *Electron J Gen Med*. 2023; 20 (6): em545.
51. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP, Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H, Subramaniyan V, Chinni SV, Ramachawolran G. Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. *Journal of Biomolecular Structure and Dynamics*. 2023:1-6.
52. Singh AK, Malviya R, Sundram S, Subramaniyan V. Big data in oncology: Extracting knowledge from machine learning. In *Big Data in Oncology: Impact, Challenges, and Risk Assessment 2023* (pp. 77-104). River Publishers.
53. Singla M, Verma S, Thakur K, Goyal A, Sharma V, Sharma D, Porwal O, Subramaniyan V, Behl T, Singh SK, Dua K. From Plants to Therapies: Exploring the Pharmacology of Coumestrol for Neurological Conditions. *Current medicinal chemistry*. 2024.
54. Alhussiney K, Othman R, Wei C, Abdullah I, Subramaniyan V. In silico Discovery of R1OK3 Inhibitors Against Pancreatic Ductal Adenocarcinoma via Molecular Docking, Molecular Dynamics Simulations, and ADMET Prediction. *Malaysian Journal of Medicine & Health Sciences*. 2024 Jan 3;20.
55. Debnath S, Elgorban AM, Bahkali AH, Eswaramoorthy R, Verma M, Syed A, Subramaniyan V, Kamaraj C, Wong LS, Kumarasamy V. Enhancing drought tolerance in cauliflower (*Brassica oleracea* var. *botrytis*) by targeting LFY transcription factor modulation via the ethylene precursor, ACCA: an innovative computational approach. *Frontiers in Plant Science*. 2024 Feb 28;15:1255979.
56. Amin Z, Alkhatibi HA, Subramaniyan V, Alreemi RM, Husn M, Fayaz W, Thatsananchalee P, Khalid A, Shah SA, Wadood A. Therapeutic Potential of 6-Amino Flavone: A Novel Approach for Diabetes and Inflammation via TNF- α /p-IRS Signaling Pathway in Albino Mice.
57. Lai J, Azad AK, Sulaiman WM, Kumarasamy V, Subramaniyan V, Alshehade SA. Alginate-Based Encapsulation Fabrication Technique for Drug Delivery: An Updated Review of Particle Type, Formulation Technique, Pharmaceutical Ingredient, and Targeted Delivery System. *Pharmaceutics*. 2024 Mar 6;16(3):370.
58. Subramaniyan V. Therapeutic importance of castor seed oil. In *Nuts and Seeds in Health and Disease Prevention 2020* Jan 1 (pp. 485-495). Academic Press.
59. Rani S, Sharma U, Deshmukh MP, Kumar V, Sharma KC, Malik MK, Subramaniyan V. Immunomodulatory and AntiOxidant Potential of Polyherbal Dhatryadi Rasayana in the Form of Churna and Granules. *ACS Omega*. 2024 Mar 19;9(13):14781-90.
60. Dh HS, Sultana R, Prabhu A, Pavan SR, Mohanto S, Subramaniyan V. Biomedicine and pharmacotherapeutic effectiveness of combinatorial atorvastatin and quercetin on diabetic nephropathy: An in vitro study. *Biomedicine & pharmacotherapy= Biomedecine & pharmacotherapie*.;174:116533.
61. Bharadwaj KK, Rabha B, Ahmad I, Mathew SP, Bhattacharjee CK, Jaganathan BG, Poddar S, Patel H,

-
- Subramaniyan V, Chinni SV, Ramachawolran G. Rhamnetin, a nutraceutical flavonoid arrests cell cycle progression of human ovarian cancer (SKOV3) cells by inhibiting the histone deacetylase 2 protein. *Journal of biomolecular structure & dynamics*.:1-6.
62. Subramaniyan V. Therapeutic Importance of Caster Seed Oil. In *Nuts and Seeds in Health and Disease Prevention 2020* (pp. 485-495). Academic Press.
63. Sharma N, Zahoor I, Sachdeva M, Subramaniyan V, Fuloria S, Fuloria NK, Naved T, Bhatia S, Al-Harrasi A, Aleya L, Bungau S. Deciphering the role of nanoparticles for management of bacterial meningitis: an update on recent studies. *Environmental Science and Pollution Research*. 2021 Nov 1:1-8.
64. Poskus, Tomas, et al. "Preventing hemorrhoids during pregnancy: a multicenter, randomized clinical trial." *BMC pregnancy and childbirth* 22.1 (2022): 374.